CoChat

Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022

Open access
Natarajan, Karthik, Prasad, Namrata, Dascomb, Kristin, Irving, Stephanie A., Yang, Duck-Hye, Gaglani, Manjusha, Klein, Nicola P., DeSilva, Malini B., Ong, Toan C., Grannis, Shaun J., Stenehjem, Edward, Link-Gelles, Ruth, Rowley, Elizabeth A., Naleway, Allison L., Han, Jungmi, Raiyani, Chandni, Benitez, Gabriela Vazquez, Rao, Suchitra, Lewis, Ned, Fadel, William F., Grisel, Nancy, Griggs, Eric P., Dunne, Margaret M., Stockwell, Melissa S., Mamawala, Mufaddal, McEvoy, Charlene, Barron, Michelle A., Goddard, Kristin, Valvi, Nimish R., Arndorfer, Julie, Patel, Palak, Mitchell, Patrick K, Smith, Michael, Kharbanda, Anupam B., Fireman, Bruce, Embi, Peter J., Dickerson, Monica, Davis, Jonathan M., Zerbo, Ousseny, Dalton, Alexandra F., Wondimu, Mehiret H., Azziz-Baumgartner, Eduardo, Bozio, Catherine H., Reynolds, Sue, Ferdinands, Jill, Williams, Jeremiah, Schrag, Stephanie J., Verani, Jennifer R., Ball, Sarah, Thompson, Mark G., Dixon, Brian E. · 2022 · MMWR. Morbidity and Mortality Weekly Report
Cited by 47

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

and 25,244 hospitalizations across 10 states during December 16, 2021-March 7, 2022, when Omicron was the predominant circulating variant.** VE against laboratory-confirmed COVID-19-associated ED/UC encounters was 24% after 1 Janssen dose, 54% after 2 Janssen doses, 79% after 1 Janssen/1 mRNA dose, and 83% after 3 mRNA doses. VE for the same vaccination strategies against laboratory-confirmed COVID-19-associated hospitalizations were 31%, 67%, 78%, and 90%, respectively. All booster strategies provided higher protection than a single Janssen dose against ED/UC visits and hospitalizations during Omicron variant predominance. Vaccination with 1 Janssen/1 mRNA dose provided higher protection than did 2 Janssen doses against COVID-19-associated ED/UC visits and was comparable to protection provided by 3 mRNA doses during the first 120 days after a booster dose. However, 3 mRNA doses provided higher protection against COVID-19-associated hospitalizations than did other booster strategies during the same time interval since booster dose. All adults who have received mRNA vaccines for their COVID-19 primary series vaccination should receive an mRNA booster dose when eligible. Adults who received a primary Janssen vaccine dose should preferentially receive a heterologous mRNA vaccine booster dose ≥2 months later, or a homologous Janssen vaccine booster dose if mRNA vaccine is contraindicated or unavailable. Further investigation of the durability of protection afforded by different booster strategies is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15585/mmwr.mm7113e2

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 5

  1. Oliver, 2022, Use of the Janssen (Johnson & Johnson) COVID-19 vaccine: updated interim recommendations from the Advisory Committee on Immunization Practices—United States, December 2021., MMWR Morb Mortal Wkly Rep, 71, 90, 10.15585/mmwr.mm7103a4 · DOI
  2. Atmar, 2022, Homologous and heterologous Covid-19 booster vaccinations., N Engl J Med, 386, 1046, 10.1056/NEJMoa2116414 · DOI · Paper page
  3. Thompson, 2021, Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings., N Engl J Med, 385, 1355, 10.1056/NEJMoa2110362 · DOI · Paper page
  4. Embi, 2021, Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—nine states, January–September 2021., MMWR Morb Mortal Wkly Rep, 70, 1553, 10.15585/mmwr.mm7044e3 · DOI · Paper page
  5. Mayr, 2022, Effectiveness of homologous or heterologous Covid-19 boosters in veterans., N Engl J Med, 10.1056/NEJMc2200415 · DOI

Cited by

See all 47

Metadata

Authors
Natarajan, K., Prasad, N., Dascomb, K., Irving, S. A., Yang, D.-H., Gaglani, M., Klein, N. P., DeSilva, M. B., Ong, T. C., Grannis, S. J., Stenehjem, E., Link-Gelles, R., Rowley, E. A., Naleway, A. L., Han, J., Raiyani, C., Benitez, G. V., Rao, S., Lewis, N., Fadel, W. F., Grisel, N., Griggs, E. P., Dunne, M. M., Stockwell, M. S., Mamawala, M., McEvoy, C., Barron, M. A., Goddard, K., Valvi, N. R., Arndorfer, J., Patel, P., Mitchell, P. K., Smith, M., Kharbanda, A. B., Fireman, B., Embi, P. J., Dickerson, M., Davis, J. M., Zerbo, O., Dalton, A. F., Wondimu, M. H., Azziz-Baumgartner, E., Bozio, C. H., Reynolds, S., Ferdinands, J., Williams, J., Schrag, S. J., Verani, J. R., Ball, S., Thompson, M. G., & Dixon, B. E.
Venue
MMWR. Morbidity and Mortality Weekly Report
Published
2022-04-01
Volume
71
Issue
13
Pages
495-502
ISSN
  • 0149-2195 (ISSN-L)
  • 1545-861X
OpenAlex
W4220887537
Cited by
47
References
1
FWCI
5.22
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022. https://app.cochat.ai/papers/10.15585/mmwr.mm7113e2
The paper
Natarajan, K., Prasad, N., Dascomb, K., Irving, S. A., Yang, D.-H., Gaglani, M., Klein, N. P., DeSilva, M. B., Ong, T. C., Grannis, S. J., Stenehjem, E., Link-Gelles, R., Rowley, E. A., Naleway, A. L., Han, J., Raiyani, C., Benitez, G. V., Rao, S., Lewis, N., . . . Dixon, B. E. (2022). Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7113e2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.